Patents by Inventor Anneliese Schneider

Anneliese Schneider has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES BINDING TO GPRC5D
    Publication number: 20220259318
    Abstract: The present invention generally relates to antibodies that bind to GPRC5D, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: January 28, 2022
    Publication date: August 18, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ALEXANDER BUJOTZEK, TONY CHRISTOPEIT, TANJA FAUTI, GEORG FERTIG, HÉLÈNE CÉCILE HAEGEL, CHRISTIAN KLEIN, THOMAS KRAFT, STEFAN LORENZ, MAUD LÉA MAYOUX, ANNELIESE SCHNEIDER
  • Method for selective oligonucleotide modification
    Patent number: 8936910
    Abstract: Method for producing a modified oligonucleotide, wherein at least one polymer, preferably polyalkylene oxide, and/or a compound is covalently bound to the 5?-end or the 3?-end of the oligonucleotide via native ligation forming a native ligation site, with the proviso that the polymer and/or the compound is not a protein or peptide, if only the 5?-end of the oligonucleotide is modified by binding of the polymer or compound via native ligation. The invention is further directed to a modified oligonucleotide obtainable by the inventive method as well as the use of such modified oligonucleotide for the preparation of a medicament for preventing and/or treating a tumor, formation of metastasis, an immune disease or disorder, a cardiovascular disease or disorder, and/or a viral disease or disorder.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: January 20, 2015
    Assignee: Antisense Pharma GmbH
    Inventors: Andreas Mitsch, Karl-Hermann Schlingensiepen, Bernd Betzler, Frank Jaschinski, Anneliese Schneider
  • METHOD FOR SELECTIVE OLIGONUCLEOTIDE MODIFICATION
    Publication number: 20130172238
    Abstract: Method for producing a modified oligonucleotide, wherein at least one polymer, preferably polyalkylene oxide, and/or a compound is covalently bound to the 5?-end or the 3?-end of the oligonucleotide via native ligation forming a native ligation site, with the proviso that the polymer and/or the compound is not a protein or peptide, if only the 5?-end of the oligonucleotide is modified by binding of the polymer or compound via native ligation. The invention is further directed to a modified oligonucleotide obtainable by the inventive method as well as the use of such modified oligonucleotide for the preparation of a medicament for preventing and/or treating a tumor, formation of metastasis, an immune disease or disorder, a cardiovascular disease or disorder, and/or a viral disease or disorder.
    Type: Application
    Filed: June 10, 2011
    Publication date: July 4, 2013
    Inventors: Andreas Mitsch, Karl-Hermann Schlingensiepen, Bernd Betzler, Frank Jaschinski, Anneliese Schneider
  • Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system
    Patent number: 8476246
    Abstract: Pharmaceutical composition comprising a chemotherapeutic agent and a TGF-beta antisense oligonucleotide, wherein the antisense oligonucleotide reduces the sensitivity and IC50, respectively, of the cytotoxicity of the chemotherapeutic agent. Preferably, the antisense oligonucleotide is a TGF-beta 1, 2, and/or 3 antisense oligonucleotide and the chemotherapeutic agent is preferably gemcitabine, 5-fluorouracil, temozolomide, dacarbacine, docetaxel, cisplatin, oxaliplatin, tamoxifen, or irinotecan.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: July 2, 2013
    Assignee: Antisense Pharma GmbH
    Inventors: Karl-Hermann Schlingensiepen, Frank Jaschinski, Tanja Rothammer-Hampl, Anneliese Schneider
  • COMBINED TREATMENT OF CANCER BY UROKINASE INHIBITION AND A CYTOSTATIC ANTI-CANCER AGENT FOR ENHANCING THE ANTI-METASTATIC EFFECT
    Publication number: 20120165287
    Abstract: The present invention relates to a combined treatment of cancer using a urokinase inhibitor and a cytotoxic or a cytostatic agent.
    Type: Application
    Filed: March 2, 2012
    Publication date: June 28, 2012
    Applicant: Wilex AG
    Inventors: Wolfgang SCHMALIX, Anneliese Schneider, Buddy Setyono-Han, Johannes Foekens
  • COMBINATION OF A CHEMOTHERAPEUTIC AGENT AND AN INHIBITOR OF THE TGF-BETA SYSTEM
    Publication number: 20120027873
    Abstract: Pharmaceutical composition comprising a chemotherapeutic agent and a TGF-beta antisense oligonucleotide, wherein the antisense oligonucleotide reduces the sensitivity and IC50, respectively, of the cytotoxicity of the chemotherapeutic agent. Preferably, the antisense oligonucleotide is a TGF-beta 1, 2, and/or 3 antisense oligonucleotide and the chemotherapeutic agent is preferably gemcitabine, 5-fluorouracil, temozolomide, dacarbacine, docetaxel, cisplatin, oxaliplatin, tamoxifen, or irinotecan.
    Type: Application
    Filed: July 30, 2010
    Publication date: February 2, 2012
    Applicant: ANTISENSE PHARMA GMBH
    Inventors: Karl-Hermann Schlingensiepen, Frank Jaschinski, Tanja Rothammer-Hampl, Anneliese Schneider
  • Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect
    Publication number: 20080226624
    Abstract: The present invention relates to a combined treatment of cancer using a urokinase inhibitor and a cytotoxic or a cytostatic agent.
    Type: Application
    Filed: March 7, 2008
    Publication date: September 18, 2008
    Inventors: Wolfgang Schmalix, Anneliese Schneider, Buddy Setyono-Han, Johannes Foekens